Dual inhibition of this pathway in patients with unresectable V600 BRAF-mutated melanoma, using combination therapy with BRAF and MEK inhibitors, confers high response rates and survival benefit, although efficacy, in metastatic patients, is often limited by development of resistance. Here, MAP2K7 is linked to melanoma.